AUS
NZ
UK
CA
USA
IND
Highlights
- Interim trial data for SNT-5505 shows promising results for Syntara (SNT).
- Improvements observed in symptoms and spleen volume among patients.
- The drug shows strong tolerability and potential long-term benefits.
Syntara Ltd (ASX:SNT) has announced encouraging interim results from its ongoing Phase 2 clinical trial for SNT-5505, a drug candidate targeting myelofibrosis (MF). These findings, which will be showcased at the 66th American Society of Hematology annual meeting (ASH), highlight the candidate's potential in improving both symptom management and spleen volume reduction in MF patients.
The trial evaluates SNT-5505 in combination with ruxolitinib, a widely used therapy for MF. Among the interim results, 46% of patients achieved a 50% improvement in Total Symptom Score (TSS50) after 12 weeks of treatment. This improvement further increased, with 80% of patients reaching the same benchmark at the 38-week mark. TSS50 is a critical measure of treatment efficacy, commonly used as a primary endpoint in MF clinical trials.
In addition to symptom improvement, spleen volume reduction (SVR) emerged as a significant marker of progress. Approximately 30% of evaluable patients achieved an SVR of 25%, and 20% reported an SVR of 35%. These results indicate consistent enhancement in both symptom management and physical outcomes over the treatment period, distinguishing SNT-5505 from other drugs currently available or in advanced development stages.
Professor Claire Harrison, an expert in myeloproliferative neoplasms at Guy’s and St Thomas’ NHS Foundation Trust, emphasized the significance of these findings. She highlighted the drug's strong safety profile and its apparent capacity for sustained therapeutic effects.
“This interim data confirms the excellent safety profile of SNT-5505 and suggests that its mechanism may provide a long-term impact on the disease,” she noted. “We are observing continuous improvement in both symptoms and spleen volume, even after nine months of treatment, which is unprecedented for this class of therapy.”
The potential for SNT-5505 to deliver long-term benefits is particularly notable, offering hope to patients grappling with MF’s debilitating symptoms and complications. While the trial remains in progress, these interim findings underline the drug's potential to address critical unmet needs in MF treatment.
Syntara (SNT) is expected to continue its research efforts, with further data anticipated in the coming months to validate these promising early outcomes. The clinical community is closely monitoring the results, as SNT-5505 could represent a significant advancement in the treatment landscape for myelofibrosis.
